Status:
UNKNOWN
Beta Blocker De-prescription Following Coronary Artery Bypass Graft Surgery (BEEFBURGER Trial).
Lead Sponsor:
University of Saskatchewan
Collaborating Sponsors:
Canadian VIGOUR Centre
Conditions:
Coronary Artery Disease
Acute Myocardial Infarction
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Beta-blockers have the greatest cardiovascular impact in patients with reduced heart function/heart failure and in reducing the peri-operative risk of atrial fibrillation. In patients without these hi...
Detailed Description
This is an open-label, non-inferiority, randomized comparison of beta-blocker continuation versus de-prescription at the 6-8 week follow-up following isolated and uncomplicated CABG at Royal Universit...
Eligibility Criteria
Inclusion
- Age ≥ 18 years treated with index isolated CABG
- Able to consent to study
- On beta blocker therapy at the 6-8week visit
- LV systolic function (≥45% assessed within 6months of CABG date)
Exclusion
- Prior heart failure with reduced ejection fraction (LVEF \<45%)
- Pre- or peri-operative atrial fibrillation or flutter
- Peri-CABG stroke
- Unable to follow-up
Key Trial Info
Start Date :
August 23 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 31 2025
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT04788186
Start Date
August 23 2021
End Date
August 31 2025
Last Update
November 9 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Royal University Hospital
Saskatoon, Saskatchewan, Canada, S7N 0W8